Similar Articles |
|
Pharmaceutical Executive July 1, 2005 Ken Dec |
Direct to Consumer: Moving House The "House of Brands" model is a house of cards. The pharmaceutical industry should change, or risk losing trust forever. |
Pharmaceutical Executive April 1, 2007 Porth & Sillup |
Media Audit: Stop the Presses! The media are becoming more negative and one-sided when it comes to reporting pharmaceutical industry news. |
Pharmaceutical Executive March 1, 2009 Porth & Sillup |
Fifth Annual Press Audit: Safety in the Spotlight Reporters pass on the typical litany of lightning-rod issues and instead devote more than three-quarters of all coverage in 2008 to drug safety and the regulators who enforce it. |
Pharmaceutical Executive June 1, 2005 Zimmerman & Fay |
Marketing to Professionals: Dr. Ambassador The pharma industry is under siege in the news media. Smart companies must create a role for physicians as ambassadors who can raise patient confidence in drugs and the pharma industry as a whole. |
Pharmaceutical Executive July 30, 2007 |
Direct to Consumer: Creativity Through Understanding Creative consumer campaigns begin with a clear understanding of pharma rules and regulations. |
Pharmaceutical Executive February 1, 2006 Chandler & Chicco |
Public Relations: Damage Control Unless pharma defines a compelling story, and defends it vigorously in the consumer marketplace, others will enter that vacuum and tell the story for it -- in far less flattering ways |
Pharmaceutical Executive June 1, 2007 Stan Bernard |
Consumerization: Pandora's Pillbox By going direct-to-consumer, the industry unwittingly unleashed a swarm of opportunities for other players to enter the pharmaceutical fray. And they made the most of it. Now, a decade later, pharma is feeling the fallout in consumer trust and product value. It's time to take back control. |
BusinessWeek November 29, 2004 Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
Pharmaceutical Executive January 1, 2007 |
Thoughtleader: Peter Pitts. DrugWonks.com Here, the chief voice of a blog hosted by the non-profit Center for Medicine in the Public Interest urges pharma to continuously plug its positions and get politics out of science, and offers some perspective on important regulatory reforms facing the FDA. |
Pharmaceutical Executive July 1, 2005 Sarah Houlton |
Global Report: Still Waiting Pharma industry and traders both want a decision on parallel trade in Europe--but not the same one. |
Pharmaceutical Executive February 1, 2006 Porth & Sillup |
Annual Press Audit: Front Page Pharma Newspapers in a study pool published more than twice as many front-page and editorial-page stories on the pharmaceutical industry than they did last year. |
Pharmaceutical Executive November 1, 2013 Jill Wechsler |
Transparency Troubles for Pharma High prices, murky financial relations, and a reluctance to disclose clinical data undermine public trust in industry and the research enterprise. |
Pharmaceutical Executive December 1, 2006 Ragnar Lofstedt |
Back Page: The Post-Trust World People no longer put their faith in industry or regulators. What can we do about that? A good start would be understanding the human side of risk. |
The Motley Fool February 28, 2011 Dan Dzombak |
Rising Star Buy: Philip Morris International Why this tobacco king is worth buying. |
Pharmaceutical Executive December 1, 2008 Patrick Clinton |
Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry. |
BusinessWeek October 18, 2004 Catherine Arnst |
The Waning of the Blockbuster Drug What's promising now are drugs that target niche diseases. That means painful restructuring ahead for Big Pharma |
BusinessWeek August 13, 2007 Arlene Weintraub |
Putting Drug Ads Back In The Bottle Efforts to curb direct-to-consumer drug advertising are growing, but so far have met little success. |
Pharmaceutical Executive March 1, 2012 Sillup & Porth |
Pharma & The Press Our eighth annual press audit finds the industry out of the crosshairs for now. |
Pharmaceutical Executive April 1, 2005 |
Thought Leader: Better Business: Balancing Benefit, Risk, and Cost An interview with author and Harvard Medical School professor Dr. Jerry Avorn on how losing track of patient welfare and failing to address important safety problems isn't just bad science and bad ethics, it's also bad business. |
Pharmaceutical Executive October 1, 2006 Sarah Houlton |
Global Report: Please Come Back Health authorities in Europe are working hard to reestablish their countries as preferred locations for pharma's R&D facilities. Fortunately, they've got a blueprint: China. |
The Motley Fool July 2, 2010 Colleen Paulson |
Government Snuffs Marlboro's Lights FDA's moves to control cigarette labeling and packaging take a bite. |
Pharmaceutical Executive January 1, 2006 Jeannette Park |
Thought Leader: Q&A with Cheryl Buxton Cheryl Buxton talks about what impact Merck's decision to cut nearly 11 percent of its work force - in hopes of saving $4 billion dollars by 2010 - will have on the company's future. |
The Motley Fool May 26, 2009 Colleen Paulson |
What's Your MO, Altria? Altria is actively supporting FDA regulation of cigarettes. Read on to see why. |
Pharmaceutical Executive March 1, 2013 Sillup et al. |
Back in the News Big Pharma takes a fresh licking in our latest audit of US press coverage of business and policy issues. |
Pharmaceutical Executive January 1, 2007 Glass & Poli |
Forecast 2007: Connecting the Dots How do execs rank the issues facing the pharmaceutical industry? And what are the links they see between them? A new study reveals the industry's mental map of today's challenges. |
Pharmaceutical Executive August 1, 2006 Patrick Clinton |
From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible. |
The Motley Fool November 10, 2009 Colleen Paulson |
Altria's Not Tobacco's Only Altruist Reynolds American may purchase a quit-smoking company. |
The Motley Fool September 9, 2004 Charly Travers |
The Case for Drug Stocks The reports of the drug industry's death are greatly exaggerated. |
Pharmaceutical Executive January 1, 2007 Walter Armstrong |
Forecast 2007: At Sea In times of crisis, it's harder than ever to take the long view. The healing arts may be as old as humankind, but the business of pharma is still in its infancy. |
The Motley Fool October 7, 2004 Brian Gorman |
Pfizer Will Weather the Storm The company will likely come out on top regardless of the outcome of the latest controversies. Pfizer remains a quality choice for long-term investors. |
Chemistry World May 2006 Bea Perks |
Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation. |
Pharmaceutical Executive October 1, 2008 |
Getting Personal(ized) Stop worrying about shrinking the market for your drug, and start figuring out how the "test and treat" business model works. |
Pharmaceutical Executive December 1, 2005 Patrick Clinton |
PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products. |
Pharmaceutical Executive April 1, 2011 |
Restoring Public Trust in Pharma Putting the focus on four steps to cement a new compliance culture. |
Pharmaceutical Executive October 1, 2005 Brad Miles |
Value Today for Drugs Tomorrow The industry can help its bad rep by communicating the promise of its pipeline -- and the value of its companies. |
The Motley Fool September 30, 2008 Brian Orelli |
Pharma, Cash, and You Pharma's been saving for a rainy day, and there's a thunderstorm outside. |
The Motley Fool January 7, 2010 Colleen Paulson |
Big Tobacco Is Back to Business Philip Morris USA touts "lower risk" smokeless tobacco. |
Bio-IT World April 2007 Malorye Allison |
Biomarkers versus Blockbusters Are companies really changing their strategies and using biomarkers to target smaller, better defined patient sets with their new drugs? Or is the vast majority of pharma biomarker studies just aimed at culling bad drugs from their pipelines? |
The Motley Fool July 23, 2009 Colleen Paulson |
Maybe Altria Is Better Off Without Philip Morris Philip Morris earnings are hit by unfavorable currency exchange. |
BusinessWeek February 28, 2005 Capell & Carey |
A Drug Watchdog To Rival The FDA Europe's agency will soon have new powers. Will it take the lead on safety? |
Pharmaceutical Executive January 1, 2006 Sarah Houlton |
Global Report: The UK's New Code of Conduct Pharma companies' relationships with doctors are being tightened in the United Kingdom, after a major overhaul of the Association of the British Pharmaceutical Industry's Code of Practice. |
The Motley Fool February 22, 2005 Charly Travers |
Is Big Pharma a Bargain? While much of the drug sector is looking pretty tasty, Pfizer, with its attractive relative valuation, dominant marketing presence, and willingness to buy up blockbuster drugs, heads the list. |
Chemistry World July 10, 2012 |
Interview: EMA head Guido Rasi His five-year appointment comes during a period of dramatic change for the pharma industry, which is struggling with patent expirations for many of its biggest selling drugs and a paucity of new drugs coming through the pipeline to take their place. |
Pharmaceutical Executive October 1, 2005 |
Public Relations: Communications Delivery Chain An interview with Nanccy Turett, president of Edelman Health on how, to regain consumers' trust, pharma must better communicate its mission, goals, and policies. |
The Motley Fool June 15, 2010 Julie Clarenbach |
Is This the Best Tobacco Buy? Who are the major tobacco retailers and how do they stack up to one another? |
Pharmaceutical Executive July 3, 2007 |
Direct to Consumer: The Secret of My Success Pharmaceutical industry experts sound off on the methods behind an award-winning ad and how the next great direct-to-consumer campaign will come about. |
Reason April 2001 Ronald Bailey |
Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry? |
The Motley Fool January 2, 2004 Selena Maranjian |
Philip Morris Cuts Prices Will the cigarette maker's price cuts for wholesalers help boost profits? |
Bio-IT World December 10, 2002 Malorye Branca |
The Trouble with Pharmaceutical Innovation There's a lot of one kind, but not enough of another in pharma land. Too many new technologies and too few new drugs -- that sums up the state of pharmaceutical R&D. |
The Motley Fool July 20, 2009 Colleen Paulson |
A World of Growth for Philip Morris? Philip Morris continues its global expansion through acquisition. |